No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NTLA Intellia Therapeutics
- 21.570
- +0.250+1.17%
Close Apr 19 16:00 ET
- 21.640
- +0.070+0.32%
Post 19:12 ET
2.07BMarket Cap-3979P/E (TTM)
21.630High20.780Low1.46MVolume21.220Open21.320Pre Close31.10MTurnover1.54%Turnover RatioLossP/E (Static)96.11MShares47.48052wk High1.97P/B2.04BFloat Cap20.78052wk Low--Dividend TTM94.53MShs Float202.730Historical High--Div YieldTTM3.99%Amplitude9.180Historical Low21.340Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Intellia Therapeutics Welcomes New Principal Accounting Officer
2 Stocks Down 30% to Buy Right Now
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Intellia Therapeutics (NASDAQ:NTLA Shareholders Incur Further Losses as Stock Declines 9.9% This Week, Taking Three-year Losses to 65%
Comments
Cathie Wood vs Warren Buffett
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF(ARKK.US$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B(BRK.B.US$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
ColumnsGene Editing: Is This "Turning Point in Medicine" a Potential Source of Blockbuster Revenue?
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
